Clinical Trials
229 trialsMultimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
DISRUPT
Icahn School of Medicine at Mount Sinai
Detection of Cancer in Breath Samples by Trained Detection Dogs
SpotitEarly
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
FHAMe
University of Toronto
ICCE-Mito
University of Nottingham
AH-HA
Wake Forest University Health Sciences
Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT Study
Fred Hutchinson Cancer Center
MiGHT
University of Michigan Rogel Cancer Center
CATALYST
Rutgers, The State University of New Jersey
Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study
National Cancer Institute (NCI)
FEGALA
Centre Paul Strauss
PREPARE
Institut Bergonié
KANSURVIVE
University of Kansas Medical Center
E-PROOF
Ohio State University Comprehensive Cancer Center
Mobile Sensor Technologies to Assess General Symptomology of People With Cancer
National Institutes of Health Clinical Center (CC)
IMPLICATION
Centre Hospitalier Universitaire de Besancon
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
GAP
University of California, Davis
Periop ctDNA
Centre Hospitalier Universitaire de Nīmes
QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
NantCell, Inc.
INOVOLINE
Hospices Civils de Lyon
FIDURA
Sahlgrenska University Hospital
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
EARN
Washington University School of Medicine
OLAP
AstraZeneca
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Novita Pharmaceuticals, Inc.
PRIORITY
Institut Bergonié
EXERCISING TOGETHER for Couples Coping With Cancer
OHSU Knight Cancer Institute
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
A Digital Therapeutic Solution for Cancer Patients
Sidekick Health
A Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and Rectum
Instituto de Investigacion Sanitaria La Fe
Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Abramson Cancer Center at Penn Medicine
PREFER
Labcorp Corporation of America Holdings, Inc
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Improving Evidence-Based Care for Cancer Patients
Medical University of South Carolina
HERO
Rutgers, The State University of New Jersey
PRECANU
Aalborg University Hospital
REMOVE
Lindis Bloodcare GmbH
ROOT
Taproot Health
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Astellas Pharma Inc
EX-MED
Karolinska Institutet
IVY
Eli Lilly and Company
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Vincerx Pharma, Inc.
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
Mayo Clinic